No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes

D. Iafusco, C. Bizzarri, F. Cadario, R. Pesavento, G. Tonini, S. Tumini, V. Cauvin, C. Colombo, R. Bonfanti, F. Barbetti

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)2736-2738
Number of pages3
Issue number10
Publication statusPublished - Oct 2011


  • Chronic
  • Durability
  • Efficacy
  • Glibenclamide
  • KCNJ11 gene
  • Kir6.2
  • Mutations
  • Permanent neonatal diabetes
  • Sulfonylurea
  • Therapy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this